A Phase 3, Randomized, Double blind, Placebo controlled Study to Evaluate the Efficacy and Safety of Filgotinib in Subjects with Active Psoriatic Arthritis Who Have an Inadequate Response or are Intolerant to Biologic DMARD Therapy.
- Year: 2020
- Type: Musculoskeletal
- Phase: III
- Indication: Psoriatic Arthritis